Sygnature Discovery

Kerry Waters
Business Development Director 
Rachel Hemsley
Business Development Director 

The Science Behind

The Science Behind specialise in integrating cutting-edge non-invasive neurostimulation and neuroimaging technologies and services to enhance Phase I clinical trials.

 

Innovatively applying techniques such as transcranial magnetic stimulation (TMS), quantitative sensory testing (QST) and electroencephalography (EEG), either independently or in combination with cognitive or physiological assessments, The Science Behind excels in addressing crucial questions related to target engagement, dose response and the timing of efficacy.

 

Our approach provides information on how a drug impacts various aspects of central nervous system function. This deeper insight into the neural mechanisms of drug action in humans serves to guide the development of new treatments, potentially enhancing their prospects for success in future clinical trials.

Soffia Cahill
LinkedIn logo Research Specialist 
Tonia Smreczak
LinkedIn logo Managing Director 

Theramex

Paula Kowalska
Senior Manager 

Vernalis

Vernalis collaborates with a wide range of organisations to enable drug discovery programs through both short- and long-term projects. By applying our deep and wide expertise in structure-based drug discovery, built over twenty-five years of partnerships and innovation to enable challenging targets, we can express and engineer your proteins, find and validate hits and help to evolve your chemical series into pre-clinical candidates. And we can do all this in-house at our fully equipped laboratories in Cambridge UK.

Ben Davis
LinkedIn logo Research Fellow and Director of Business Development 

ViaNautis

ViaNautis is exploiting its proprietary technology, polyNaut®, a nanovesicle platform using advanced polymer materials and machine learning, to direct nucleic acid therapeutics to the specific site of action with unparalleled precision.
Sam Barker
LinkedIn logo Chief Business Officer